These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22257653)

  • 1. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review.
    Arcangeli S; Scorsetti M; Alongi F
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):101-8. PubMed ID: 22257653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies.
    Teh BS; Ishiyama H; Mathews T; Xu B; Butler EB; Mayr NA; Lo SS; Lu JJ; Blanco AI; Paulino AC; Timmerman RD
    Discov Med; 2010 Sep; 10(52):255-62. PubMed ID: 20875347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond].
    Teh BS; Paulino A; Butler EB
    Ai Zheng; 2008 Aug; 27(8):885-93. PubMed ID: 18710628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging application of stereotactic body radiation therapy for gynecologic malignancies.
    Mayr NA; Huang Z; Sohn JW; Lo SS; Teh BS; Lu JJ; Grecula JC; Kunos C
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1069-75. PubMed ID: 21806330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?
    Zaorsky NG; Studenski MT; Dicker AP; Gomella L; Den RB
    Cancer Treat Rev; 2013 May; 39(3):212-8. PubMed ID: 23218442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
    King CR; Brooks JD; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.
    Buyyounouski MK; Price RA; Harris EE; Miller R; Tomé W; Schefter T; Parsai EI; Konski AA; Wallner PE
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1297-304. PubMed ID: 20338473
    [No Abstract]   [Full Text] [Related]  

  • 11. Stereotactic body radiation therapy: a novel treatment modality.
    Lo SS; Fakiris AJ; Chang EL; Mayr NA; Wang JZ; Papiez L; Teh BS; McGarry RC; Cardenes HR; Timmerman RD
    Nat Rev Clin Oncol; 2010 Jan; 7(1):44-54. PubMed ID: 19997074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for prostate cancer.
    Henderson DR; Tree AC; van As NJ
    Clin Oncol (R Coll Radiol); 2015 May; 27(5):270-9. PubMed ID: 25707911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of stereotactic body radiation therapy in gastrointestinal malignancies in locally advanced and metastatic settings.
    Khrizman P; Small W; Dawson L; Benson AB
    Clin Colorectal Cancer; 2010 Jul; 9(3):136-43. PubMed ID: 20643617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for prostate cancer.
    Ishiyama H; Teh BS; Lo SS; Mathews T; Blanco A; Amato R; Ellis RJ; Mayr NA; Paulino AC; Xu B; Butler BE
    Future Oncol; 2011 Sep; 7(9):1077-86. PubMed ID: 21919695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for prostate cancer-a review.
    Haque W; Butler EB; Teh BS
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy: a critical review for nonradiation oncologists.
    Kirkpatrick JP; Kelsey CR; Palta M; Cabrera AR; Salama JK; Patel P; Perez BA; Lee J; Yin FF
    Cancer; 2014 Apr; 120(7):942-54. PubMed ID: 24382744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pushing the limits of radiation therapy for prostate cancer: where do we go next?
    Mishra MV; Showalter TN
    Semin Oncol; 2013 Jun; 40(3):297-307. PubMed ID: 23806495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.